638 related articles for article (PubMed ID: 23130564)
21. [Differential diagnosis and strategy for the treatment of anaplastic thyroid carcinoma].
Suzuki S
Nihon Rinsho; 2007 Nov; 65(11):2079-86. PubMed ID: 18018574
[TBL] [Abstract][Full Text] [Related]
22. [Personalized approach to anaplastic thyroid carcinoma].
Wächter S; Bartsch DK; Maurer E
Chirurgie (Heidelb); 2024 Mar; 95(3):192-199. PubMed ID: 37973622
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and Management of Anaplastic Thyroid Cancer.
Chintakuntlawar AV; Foote RL; Kasperbauer JL; Bible KC
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):269-284. PubMed ID: 30717908
[TBL] [Abstract][Full Text] [Related]
24. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
25. Poorly differentiated and anaplastic thyroid cancer.
Patel KN; Shaha AR
Cancer Control; 2006 Apr; 13(2):119-28. PubMed ID: 16735986
[TBL] [Abstract][Full Text] [Related]
26. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
[TBL] [Abstract][Full Text] [Related]
27. The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines.
Silver Karcioglu A; Iwata AJ; Pusztaszeri M; Abdelhamid Ahmed AH; Randolph GW
Cancer Cytopathol; 2022 Mar; 130(3):174-180. PubMed ID: 34618407
[No Abstract] [Full Text] [Related]
28. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches.
Ain KB
Thyroid; 1998 Aug; 8(8):715-26. PubMed ID: 9737368
[TBL] [Abstract][Full Text] [Related]
29. Comparing outcomes in poorly-differentiated versus anaplastic thyroid cancers treated with radiation: a surveillance, epidemiology, and end results analysis.
Arora S; Christos P; Pham A; Desai P; Wernicke AG; Nori D; Chao KS; Parashar B
J Cancer Res Ther; 2014; 10(3):526-30. PubMed ID: 25313732
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of anaplastic thyroid carcinoma in the Kurdistan region of Iraq.
Mustafa DH; Ahmed BS; Haweizy RM; Dewana AM
BMC Surg; 2022 Oct; 22(1):364. PubMed ID: 36271386
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic Thyroid Cancer: New Horizons and Challenges.
Maniakas A; Zafereo M; Cabanillas ME
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):391-401. PubMed ID: 35662448
[TBL] [Abstract][Full Text] [Related]
32. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer.
Cabanillas ME; Williams MD; Gunn GB; Weitzman SP; Burke L; Busaidy NL; Ying AK; Yiin YH; William WN; Lu C; Lai SY
Head Neck; 2017 Jul; 39(7):1291-1295. PubMed ID: 28452157
[TBL] [Abstract][Full Text] [Related]
33. Survival and prognostic factors of anaplastic thyroid carcinoma.
Paunovic IR; Sipetic SB; Zoric GV; Diklic AD; Savic DV; Marinkovic J; Zivaljevic VR
Acta Chir Belg; 2015; 115():62-7. PubMed ID: 26021793
[TBL] [Abstract][Full Text] [Related]
34. [Anaplastic carcinoma of the thyroid: diagnosis and treatment].
Giuffrida D; Lavenia G; Aiello RA; Di Blasi C; Gambera G; Pappalardo A; Petralia G; Ursino M; Failla G
Clin Ter; 2001; 152(4):255-61. PubMed ID: 11725619
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma.
Higashiyama T; Ito Y; Hirokawa M; Fukushima M; Uruno T; Miya A; Matsuzuka F; Miyauchi A
Thyroid; 2010 Jan; 20(1):7-14. PubMed ID: 20025538
[TBL] [Abstract][Full Text] [Related]
36. Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report.
Zheng L; Li L; He Q; Wang M; Ma Y; Zhu J; Li Y; Fu X; Zhang Y
Medicine (Baltimore); 2021 Aug; 100(32):e26138. PubMed ID: 34397868
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic thyroid carcinoma: a 50-year experience at a single institution.
McIver B; Hay ID; Giuffrida DF; Dvorak CE; Grant CS; Thompson GB; van Heerden JA; Goellner JR
Surgery; 2001 Dec; 130(6):1028-34. PubMed ID: 11742333
[TBL] [Abstract][Full Text] [Related]
38. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy.
Yau T; Lo CY; Epstein RJ; Lam AK; Wan KY; Lang BH
Ann Surg Oncol; 2008 Sep; 15(9):2500-5. PubMed ID: 18581185
[TBL] [Abstract][Full Text] [Related]
39. What is the gold standard for comprehensive interinstitutional communication of perioperative information for thyroid cancer patients? A comparison of existing electronic health records with the current American Thyroid Association recommendations.
Dos Reis LL; Tuttle RM; Alon E; Bergman DA; Bernet V; Brett EM; Cobin R; Doherty G; Harris JR; Klopper J; Lee SL; Lupo M; Milas M; Machac J; Mechanick JI; Orloff L; Randolph G; Ross DS; Smallridge RC; Terris DJ; Tufano RP; Mehra S; Scherl S; Clain JB; Urken ML
Thyroid; 2014 Oct; 24(10):1466-72. PubMed ID: 25036190
[TBL] [Abstract][Full Text] [Related]
40. ACR Appropriateness Criteria® thyroid carcinoma.
Salama JK; Golden DW; Yom SS; Garg MK; Lawson J; McDonald MW; Quon H; Ridge JA; Saba N; Smith RV; Worden F; Yeung AR; Beitler JJ
Oral Oncol; 2014 Jun; 50(6):577-86. PubMed ID: 24824115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
